BellRing Brands (BRBR) Shares Declined 19% Amid Upcoming Retailer Destocking – Hagens Berman
GlobeNewswire News Room· 2025-07-02 04:08
SAN FRANCISCO, July 01, 2025 (GLOBE NEWSWIRE) -- On May 6, 2025, investors in BellRing Brands, Inc. (NYSE: BRBR) saw the price of their shares decline about 19% after BellRing announced during its Q2 2025 earnings call that it anticipated Q3 2025 reduction in retailer inventory levels. This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether BellRing Brands may have violated the securities laws concerning the company’s sales practices. The firm urg ...
First Industrial Realty Trust To Host Second Quarter 2025 Results Conference Call On July 17
Prnewswire· 2025-07-02 04:08
CHICAGO, July 1, 2025 /PRNewswire/ -- First Industrial Realty Trust, Inc. (NYSE: FR), a leading fully integrated owner, operator and developer of logistics real estate, will host its second quarter 2025 results conference call on Thursday, July 17, 2025 at 10:00 a.m. CDT (11:00 a.m. EDT). The conference call may be accessed by dialing (833) 890-3273, passcode "First Industrial". The conference call will also be webcast live on the Investors page of the Company's website at www.firstindustrial.com.First Indu ...
Forget IBM: Accenture's AI Momentum Is Your Next Buy
MarketBeat· 2025-07-02 04:07
公司表现对比 - IBM过去52周总回报率约为76%,而Accenture的总回报率约为0% [1][2] - IBM的Gen-AI业务从开始到今年3月达到60亿美元,平均每季度增长约8.5亿美元 [3] - Accenture的Gen-AI业务在三季度内达到41亿美元,平均每季度增长约13.7亿美元,上季度增长15亿美元,比IBM的"超过10亿美元"高出50% [4] 业务发展 - Accenture的Gen-AI业务增长速度明显快于IBM,但其整体预订量上季度下降6% [5] - 公司面临宏观经济不确定性影响客户支出,政府业务放缓预计对下季度收入增长造成2%的阻力 [6][7] - Gen-AI业务目前占Accenture总业务不到8%,尚不足以显著推动整体业绩 [8] 市场观点 - 华尔街对IBM的共识目标价约为254美元,暗示13%的下行空间,而Accenture的目标价为370美元,暗示24%的上行潜力 [10] - Accenture的远期市盈率约为22倍,低于IBM的26倍 [12] - 分析师认为Accenture是长期且更便宜的投资选择,但需要耐心等待其他业务问题解决 [12] 未来展望 - Accenture正在通过Gen-AI推动"重塑",这可能蚕食其他收入流,但长期来看有利于公司在AI咨询领域的领先地位 [7] - 公司面临领导层变动和服务部门重组等内部挑战 [8] - Gen-AI对公司的长期成功至关重要,当前进展为未来几年奠定了良好基础 [9]
Digital Realty Schedules Second Quarter 2025 Earnings Release and Conference Call
Prnewswire· 2025-07-02 04:05
公司公告 - Digital Realty将于2025年7月24日市场收盘后发布2025年第二季度财务业绩 [1] - 公司计划在2025年7月24日美国东部时间下午5点/中部时间下午4点举行电话会议讨论业绩 [1] 投资者参与方式 - 投资者可通过拨打电话+1 (888) 317-6003(美国境内)或+1 (412) 317-6061(国际)参与实时电话会议 会议ID为5545220 [2] - 实时网络直播将在Digital Realty官网投资者关系板块提供 [2] - 电话和网络重播将在会议结束后一小时内提供 持续至2025年8月24日 [3] - 重播电话可拨打+1 (877) 344-7529(美国境内)或+1 (412) 317-0088(国际) 会议ID为4783857 [3] 公司概况 - Digital Realty是全球领先的云和运营商中立数据中心、托管和互联解决方案提供商 [4] - 公司PlatformDIGITAL®全球数据中心平台为客户提供安全的数据交汇场所 [4] - 采用Pervasive Datacenter Architecture (PDx®)解决方案方法论 助力创新并有效应对数据引力挑战 [4] - 全球数据中心覆盖25+国家50+大都市区 拥有300+设施 六大洲均有布局 [4]
AAR to announce fourth quarter fiscal year 2025 results on July 16, 2025
Prnewswire· 2025-07-02 04:05
WOOD DALE, Ill., July 1, 2025 /PRNewswire/ -- AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, today announced that it will release financial results for its fourth quarter of fiscal year 2025, ended May 31, 2025, after the close of the New York Stock Exchange trading session on Wednesday, July 16, 2025.On Wednesday, July 16, 2025, at 4 p.m. Central time, AAR will hold a conference call to discuss the results. A listen-only webcast and sl ...
Meta to Announce Second Quarter 2025 Results
Prnewswire· 2025-07-02 04:05
财报发布安排 - 公司将于2025年7月30日美股收盘后公布2025年第二季度财务业绩 [1] - 财报电话会议定于太平洋时间下午2点(东部时间下午5点)举行 [2] 投资者沟通渠道 - 财报电话会议直播及材料(新闻稿、财务表格、幻灯片)可通过投资者关系网站investor.atmeta.com获取 [2] - 会议回放、分析师电话会议文字记录将在同一网站发布 [2] - 公司通过investor.atmeta.com、meta.com/news及CEO社交媒体账号(Facebook、Instagram、Threads)披露重大非公开信息 [3] 公司战略定位 - 公司致力于通过人工智能和沉浸式技术构建人类连接的未来 [4] - 旗下产品(Facebook、Messenger、Instagram、WhatsApp)已连接全球数十亿用户 [4] - 当前战略重点是从2D屏幕转向促进深度连接的沉浸式体验 [4] 联系方式 - 投资者关系联系人:Kenneth Dorell [5] - 媒体联系人:Ashley Zandy [5]
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
Prnewswire· 2025-07-02 04:05
公司动态 - 公司向一名新员工授予总计17,000股普通股的期权作为雇佣激励 [1] - 期权授予由公司董事会薪酬委员会根据诱导计划批准 旨在激励员工为公司成功做出重大贡献 [2] - 期权授予依据NYSE上市公司手册303A08条款的雇佣诱导豁免规则 [2] - 期权将在授予日第一周年后归属25% 之后每月归属1/48 四年后完全归属 前提是持续受雇于公司 [3] 公司概况 - 公司是抗体药物偶联物(ADC)领域的商业化阶段全球领导者和先驱 [4] - 公司专注于通过专有ADC技术改变血液恶性肿瘤和实体瘤的治疗模式 [4] - 公司总部位于瑞士洛桑 在伦敦和新泽西设有运营机构 [6] 产品管线 - CD19靶向ADC药物ZYNLONTA已获FDA加速批准和欧盟有条件批准 用于治疗复发或难治性弥漫大B细胞淋巴瘤(二线及以上治疗) [5] - ZYNLONTA正在开发与其他药物的联合治疗方案及更早期治疗线应用 [5] - 除ZYNLONTA外 公司还有多个ADC药物处于临床和临床前开发阶段 [5] 知识产权 - ZYNLONTA是公司的注册商标 [6]
Carnival Corporation & plc Announces Pricing of €1.0 Billion 4.125% Senior Unsecured Notes Offering
Prnewswire· 2025-07-02 04:05
Proceeds from the offering of senior unsecured notes to be used to repay borrowings under the senior secured term loan facilitiesMIAMI, July 1, 2025 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) today announced that Carnival plc (the "Company") priced its private offering (the "Notes Offering") of €1.0 billion aggregate principal amount of 4.125% senior unsecured notes due 2031 (the "Notes"). The Company expects to use the proceeds from the Notes Offering to fully repay the borrowing ...
Bit Digital, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Ordinary Shares
Prnewswire· 2025-07-02 04:01
公司融资情况 - 公司宣布承销商全额行使额外购买1125万股普通股的期权 带来约2140万美元净收益[1] - 包括承销商全额行权在内 本次公开发行共发行8625万股普通股 扣除承销折扣和发行费用后净收益约1629亿美元[2] - 融资所得资金将用于购买以太坊[2] 发行相关方信息 - B Riley Securities担任本次发行的独家账簿管理人 Clear Street Craig-Hallum和Northland Capital Markets担任联合管理人[3] - 本次发行依据S-3表格注册声明进行 包括2025年4月30日提交并于2025年6月20日生效的基架招股说明书[4] 公司业务概况 - 公司是公开交易的数字资产平台 专注于以太坊原生资金管理和质押策略[6] - 自2022年开始积累并质押ETH 目前运营全球最大机构级以太坊质押基础设施之一[6] - 平台功能包括高级验证节点操作 机构级托管 主动协议治理和收益优化[6] - 通过以太坊生态系统的战略合作伙伴关系 提供安全可扩展且合规的链上收益渠道[6]
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
GlobeNewswire News Room· 2025-07-02 04:01
MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer. Ms. Sandler, who joined Oruka in 2024 as SVP of Operations, brings over 20 years of biopharmaceutical leadership experience across clinical operations, develo ...